Schizophrenia Clinical Trial
Official title:
Probing the Cannabinoid System in Individuals With a Family History of Psychosis
Verified date | May 2024 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.
Status | Active, not recruiting |
Enrollment | 21 |
Est. completion date | December 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria FHP: - Exposure to cannabis at least once in their lifetime - Medically and psychiatrically healthy based on screening - Having one relative with a confirmed psychotic disorder Exclusion Criteria FHP: - Current or lifetime major DSM-IV Axis I disorder - Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness - Major or unstable medical illness that might impact safety of the subject in the study - Cannabis naive - IQ less than 85 - Less than a high school diploma or its educational equivalent - Pregnancy or lactation - Major current or recent (<6 weeks) psychosocial stressors. Inclusion Criteria FHN : - Exposure to cannabis at least once in their lifetime - Medically and psychiatrically healthy based on screening Exclusion Criteria FHN: - Having a family member with psychosis - Current or lifetime major DSM-IV Axis I disorder - Current or lifetime treatment (at least 6 months) with psychotropic medications for major psychiatric or neurological illness - Major or unstable medical illness that might impact safety of the subject in the study - Cannabis naive - IQ less than 85 - Less than a high school diploma or its educational equivalent - Pregnancy or lactation - Major current or recent (<6 weeks) psychosocial stressors. |
Country | Name | City | State |
---|---|---|---|
United States | VA Connecticut Healthcare System | West Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive and Negative Symptom Scale for Schizophrenia (PANSS) | Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. | -30 min from administration of THC | |
Primary | Positive and Negative Symptom Scale for Schizophrenia (PANSS) | Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. | +80 min from administration of THC | |
Primary | Positive and Negative Symptom Scale for Schizophrenia (PANSS) | Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. | +150 min of administration of THC | |
Primary | Positive and Negative Symptom Scale for Schizophrenia (PANSS) | Positive, negative and general symptoms will be assessed using the positive, negative and general symptoms subscales of the PANSS. | +240 min of administration of THC | |
Secondary | Clinician Administered Dissociative Symptoms Scale (CADSS) | Perceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-report items and 8 clinician-rated items (0=not at all, 4=extremely). The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment. | -30 min, +15 min, +80 min, +150 min, +240 min | |
Secondary | Visual Analog Scale (VAS) | Feeling states associated with cannabis intoxication will be measured using a self-reported visual analogue scale of four feeling states ("high", "anxious", "calm and relaxed", and "tired") associated with cannabis effects. Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11 mm line (0=not at all, 100=extremely). These data will be captured to validate that the experiment is relevant to cannabis effects. | -30 min, +15 min, +80 min, +150 min, +240 min | |
Secondary | Hopkins Verbal Learning Test (HVLT) | The HVLT is a 12 word list that is semantically organized. The task consists of 5 trials, an interference list, and free delayed recall and recognition. A different version of the AVLT will be administered on each test day and counterbalanced across subjects. | +50 min | |
Secondary | Psychotomimetic States Inventory (PSI) | The PSI is a measure of drug induced psychotomimetic states. This self-report scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC. | -30 min, +240 min |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |